Curaleaf Holdings (CURLF) Income from Non-Controlling Interests (2019 - 2026)
Curaleaf Holdings (CURLF) posted quarterly Income from Non-Controlling Interests of -$16000.0 for Q1 2026, down 101.96% year-over-year from $817000.0 in Q1 2025, and down 100.73% quarter-over-quarter from $2.2 million in Q4 2025.
Curaleaf Holdings (CURLF) Income from Non-Controlling Interests (2019 - 2026) Analysis & Trends
Curaleaf Holdings' Income from Non-Controlling Interests history runs 8 years deep, the most recent figure standing at -$16000.0 for Q1 2026.
- In Q1 2026, Income from Non-Controlling Interests fell 101.96% year-over-year to -$16000.0; the TTM figure through Mar 2026 stood at $2.1 million (down 95.35% YoY), while the FY2025 annual figure was $2.9 million, down 92.93% from the prior year.
- Income from Non-Controlling Interests for Q1 2026 stood at -$16000.0, down from $2.2 million in the prior quarter.
- The five-year high for Income from Non-Controlling Interests was $46.9 million in Q4 2024, with the low at -$2.4 billion in Q4 2023.
- The 5-year median for Income from Non-Controlling Interests is -$230500.0 (2025), against an average of -$148.9 million.
- The sharpest annual moves came in 2024 and 2025: Income from Non-Controlling Interests plunged 5079999900.0% in 2024, then jumped 130.29% in 2025.
- Curaleaf Holdings' Income from Non-Controlling Interests stood at -$2.4 million in 2022, then tumbled by 99941.36% to -$2.4 billion in 2023, then jumped by 101.94% to $46.9 million in 2024, then tumbled by 95.31% to $2.2 million in 2025, then tumbled by 100.73% to -$16000.0 in 2026.
- Business Quant data shows CURLF's Income from Non-Controlling Interests at -$16000.0 in Q1 2026, $2.2 million in Q4 2025, and $345000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.81 Bn | 42.84 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.29 Bn | 39.63 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.59 Bn | 29.91 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.67 Bn | 22.88 Bn | 5.10 Bn | 376,434.15 |
| 5 | United Therapeutics | 22.24 Bn | 19.58 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.79 Bn | 17.91 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.71 Bn | 15.32 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 12.09 Bn | 11.56 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Curaleaf Holdings | 2.51 Bn | 2.42 Bn | 169.91 Mn | 9.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.89 Mn |
| Mar 31, 2026 | -16,000.00 |
| Dec 31, 2025 | 2.20 Mn |
| Sep 30, 2025 | 345,000.00 |
| Jun 30, 2025 | -445,000.00 |
| Mar 31, 2025 | 817,000.00 |
| Dec 31, 2024 | 46.94 Mn |
| Sep 30, 2024 | -2.03 Mn |
| Jun 30, 2024 | -945,000.00 |
| Mar 31, 2024 | -2.70 Mn |
| Dec 31, 2023 | -2.42 Bn |
| Sep 30, 2023 | -0.04 |
| Jun 30, 2023 | -3.25 Mn |
| Mar 31, 2023 | -0.06 |
| Dec 31, 2022 | -2.42 Mn |
| Sep 30, 2022 | -2.77 Mn |
| Jun 30, 2022 | 127,000.00 |
| Dec 31, 2021 | -2.54 Mn |
| Sep 30, 2021 | -2.36 Mn |
| Jun 30, 2021 | -1.84 Mn |